Evidence map›Paper›PMID 29500688›Full record

ReviewThe journal of headache and pain2018

Protective effects of PACAP in ischemia.

Dora Reglodi, Alexandra Vaczy, Eloísa Rubio-Beltran, Antoinette MaassenVanDenBrink

Open access · goldAbstract readReview
In one paragraph

Review in The journal of headache and pain, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 55 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Molecular and Physiological Functions of PACAP in Sweat Secretion.International journal of molecular sciences · 2023
    Article
  11. Role of endocrine PACAP in age-related diseases.Frontiers in endocrinology · 2023
    Review
  12. A Review on the Role of Endogenous Neurotrophins and Schwann Cells in Axonal Regeneration.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2022
    Review
  13. Article
  14. Stability Test of PACAP in Eye Drops.Journal of molecular neuroscience : MN · 2021
    Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Dora ReglodiDepartment of Anatomy, MTA-PTE PACAP Research Group, University of Pecs Medical School, Pécs, Hungary. dora.reglodi@aok.pte.hu.
Alexandra VaczyDepartment of Anatomy, MTA-PTE PACAP Research Group, University of Pecs Medical School, Pécs, Hungary.
Eloísa Rubio-BeltranDepartment of Internal Medicine, Division of Vascular Medicine and Pharmacology, Erasmus MC, Rotterdam, The Netherlands.
Antoinette MaassenVanDenBrinkDepartment of Internal Medicine, Division of Vascular Medicine and Pharmacology, Erasmus MC, Rotterdam, The Netherlands.
University of Pecs · HUErasmus MC · NLErasmus University Rotterdam · NL

Funding

EFOP EFOP-3.6.1.-16-2016-00004GINOP 2.3.2-15-2016-00050Hungarian Brain Research Foundation KTIA_13_NAP-A-III/5Magyar Tudományos Akadémia TKI14016NKFIH 119759
6 · The paper itself

Abstract

Pituitary adenylate cyclase activating polypeptide (PACAP) is an ubiquitous peptide involved, among others, in neurodevelopment, neuromodulation, neuroprotection, neurogenic inflammation and nociception. Presence of PACAP and its specific receptor, PAC1, in the trigeminocervical complex, changes of PACAP levels in migraine patients and the migraine-inducing effect of PACAP injection strongly support the involvement of PACAP/PAC1 receptor in migraine pathogenesis. While antagonizing PAC1 receptor is a promising therapeutic target in migraine, the diverse array of PACAP's functions, including protection in ischemic events, requires that the cost-benefit of such an intervention is well investigated by taking all the beneficial effects of PACAP into account. In the present review we summarize the protective effects of PACAP in ischemia, especially in neuronal ischemic injuries, and discuss possible points to consider when developing strategies in migraine therapy interfering with the PACAP/PAC1 receptor system.

Indexed as

AnimalsBrain IschemiaHumansMigraine DisordersNeuronsNeuroprotective AgentsPituitary Adenylate Cyclase-Activating PolypeptideReceptors, Pituitary Adenylate Cyclase-Activating PolypeptideReceptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type INeuroprotective AgentsPituitary Adenylate Cyclase-Activating PolypeptideReceptors, Pituitary Adenylate Cyclase-Activating PolypeptideReceptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type IIschemiaMigraineNeuroprotectionPACAP

Identifiers

PMID29500688
PMCPMC5834414
OpenAlexW2790260759

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.